Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Refractory Biliary Cancers
NCT01425879Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started Apr 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT01425879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01425879.